CCL2 and neoplasm: In the multivariate Cox’s regression analysis (adjusted to tumor stage and molecular subtype) in the N0 group, patients with negative CCL2 staining had a 1.99-fold increased risk of death, a 3.17-fold increased risk of disease-specific death, and a 3.10-fold increased risk for relapse (p = 0.014, p = 0.002, and p = 0.002; Table 5) compared to the patients with CCL2-positive staining.